Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Sexual dysfunction in treated breast cancer patients (1997)
    Springer
    Annals of oncology 8 (1997), S. 149-153 
    Details
    ISSN: 1569-8041
    Keywords: breast cancer ; quality of sex life ; sexual dysfunction
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: This study examined the impact of breast cancer therapyon women's sexuality. Patients and methods: A questionnaire concerning various sexualproblems experienced before and after treatment was anonymously completed by50 women in the outpatient clinic of our hospital's Division of RadiationOncology. To be eligible, subjects had to be disease-free and sexually active.They also had to have undergone surgery at least one year previously and havecompleted CT and/or RT. Fifty-eight percent of the women involved hadundergone mastectomy and 42% had undergone quadrantectomy followed byRT. Results: Ninety percent of the subjects continued sexual activityafter treatment, but there was an increase in the incidence of sexual problemswhich resulted in a slight reduction in the quality of their sex lives.Sixty-four percent of the women experienced an absence of sexual desire and48% low sexual desire, while 38% had dyspareunia, 44%frigidity and 42% lubrication problems. Vaginismus, brief intercourseand female orgasmic disorder were reported by 30% of the subjects.Thirty-six percent suffered from sexual dysfunction before treatment, whichworsened in about 27%, while in 49% of women sexual problemsarose mainly after chemotherapy (26%) or surgery (12%). Aboutone-half experienced changes in the relationship with their partner. Conclusion: Breast cancer patients experienced sexual dysfunction;ours found it easier to discuss the problems with their partner during theirillness (62%) than with doctors and psychologists (15%).
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008298615272
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: Endocrine and clinical results (1997)
    Springer
    Annals of oncology 8 (1997), S. 649-654 
    Details
    ISSN: 1569-8041
    Keywords: advanced disease ; aromatase inhibitors ; breast cancer ; formestane
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: In postmenopausal breast cancer (BC) patients, tamoxifen (TAM)is frequently used in first-line therapy, and for those relapsing under TAM,aromatase inhibitors would be the drug of choice. Formestane, a new aromataseinhibitor, has been demonstrated to be as effective as TAM in first-linetherapy. This trial was carried out to investigate the pharmacokinetics andantitumor activity of two formestane doses in BC patients at first relapse,as well as their effects on estrogen levels, evaluated by means of a newanalytical method. Patients and methods: One hundred fifty-two postmenopausal BC patients wererandomly given formestane 250 mg or 500 mg intramuscularly every two weeks.The blood samples for estrogen measurements were taken on the first day oftherapy, at 4 and 10 weeks, and every 12 weeks thereafter. Tumor response wasfirst evaluated after 2.5 months, and then every three months. Results: Seventy-three patients received formestane 250 mg and 79 received500 mg. After four weeks, plasma estrone, estradiol and estrone sulphatelevels were significantly (P〈0.001) suppressed in both groups. The overallresponse rates were 30% and 40% on 250 mg and 500 mg,respectively. Conclusions: Both of the formestane doses are effective in reducing plasmaestrogen levels in BC patients at first relapse, and the new analytical methodimproved the quality of results. The antitumor response was highlysatisfactory.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008270131789
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: A high-activity, dose-dense weekly regimen for advanced breast cancer (1999)
    Springer
    Annals of oncology 10 (1999), S. 937-942 
    Details
    ISSN: 1569-8041
    Keywords: breast cancer ; dose-intensity ; epirubicin ; G-CS/kwd〉 ; vinorelbine ; weekly schedule
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: This study was designed to explore the effectiveness and tolerability of a weekly regimen of epirubicin and vinorelbine plus granulocyte colony-stimulating factor (G-CSF). Patients and methods: Fifty-two patients with previously untreated advanced breast cancer were treated with epirubicin (25 mg/m2/week) and vinorelbine (25 mg/m2/week) with G-CSF support, for 24 consecutive weeks. Results: The median number of courses per patient was 22 (range 10–24). The administered dose intensity was 23 mg/m2 for both epirubicin and vinorelbine. Ten complete responses (19%) and 30 partial responses (58%) were obtained, for an overall response rate of 77%. None of the patients progressed during treatment. The median response duration and time to progression were both 10 months. A total of 1065 courses were assessed for toxicity. Grade 3 neutropenia was the most common toxic manifestation, (39% of patients), without febrile neutropenia or neutropenic sepsis. Two patients had grade 3 cardiac toxicity, which regressed without sequelae. Median survival was 31 months, with a median follow-up of 24 months (range 9–40). Conclusions: Owing to its effectiveness and tolerability, the weekly regimen of epirubicin and vinorelbine plus G-CSF may represent an acceptable alternative for patients with untreated metastatic breast cancer. It could be tested in the adjuvant and neoadjuvant setting.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008324329562
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...